Long-acting oral phosphodiesterase inhibition preconditions against reperfusion injury in an experimental lung transplantation model

Journal of Thoracic and Cardiovascular Surgery

Volumn 137, Issue 5, 2009, Pages 1249-1257

  Weiss, Eric S ^a   Champion, Hunter C ^a   Williams, Jason A ^a   Baumgartner, William A ^a   Shah, Ashish S ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; REACTIVE OXYGEN METABOLITE; TADALAFIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD GAS ANALYSIS; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL MODEL; ISCHEMIA; LUNG ARTERY PRESSURE; LUNG TRANSPLANTATION; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; CARBOLINES; CYCLIC GMP; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; LUNG TRANSPLANTATION; PHOSPHODIESTERASE INHIBITORS; PREOPERATIVE CARE; PROBABILITY; RABBITS; RANDOM ALLOCATION; REACTIVE OXYGEN SPECIES; REFERENCE VALUES; REPERFUSION INJURY; TISSUE AND ORGAN HARVESTING;

EID: 64649098038     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2008.12.040     Document Type: Article

References (30)

1. Christie J.D., Bavaria J.E., Palevsky H.I., Litzky L., Blumenthal N.P., Kaiser L.R., et al. Primary graft failure following lung transplantation. Chest 114 (1998) 51-60
2. King R.C., Binns O.A., Rodriguez F., Kanithanon R.C., Daniel T.M., Spotnitz W.D., et al. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 69 (2000) 1681-1685
3. Granton J. Update of early respiratory failure in the lung transplant recipient. Curr Opin Crit Care 12 (2006) 19-24
4. Whitson B.A., Prekker M.E., Herrington C.S., Whelan T.P., Radosevich D.M., Hertz M.I., et al. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant 26 (2007) 1004-1011
5. Whitson B.A., Nath D.S., Johnson A.C., Walker A.R., Prekker M.E., Radosevich D.M., et al. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg 131 (2006) 73-80
6. de Perrot M., Liu M., Waddell T.K., and Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 167 (2003) 490-511
7. Daud S.A., Yusen R.D., Meyers B.F., Chakinala M.M., Walter M.J., Aloush A.A., et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 175 (2007) 507-513
8. Ng C.S., Wan S., Arifi A.A., and Yim A.P. Inflammatory response to pulmonary ischemia-reperfusion injury. Surg Today 36 (2006) 205-214
9. Vural K.M., and Oz M.C. Endothelial adhesivity, pulmonary hemodynamics and nitric oxide synthesis in ischemia-reperfusion. Eur J Cardiothorac Surg 18 (2000) 348-352
10. Schutte H., Witzenrath M., Mayer K., Weissmann N., Schell A., Rosseau S., et al. The PDE inhibitor zaprinast enhances NO-mediated protection against vascular leakage in reperfused lungs. Am J Physiol 279 (2000) L496-L502
11. Featherstone R.L., Chambers D.J., and Kelly F.J. Comparison of phosphodiesterase inhibitors of differing isoenzyme selectivity added to St. Thomas' hospital cardioplegic solution used for hypothermic preservation of rat lungs. Am J Respir Crit Care Med 162 3 Pt 1 (2000) 850-856
12. Kass D.A., Takimoto E., Nagayama T., and Champion H.C. Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc Res 75 (2007) 303-314
13. Masson P., Lambert S.M., Brown M., and Shabsigh R. PDE-5 inhibitors: current status and future trends. Urol Clin North Am 32 (2005) 511-525 viii
14. Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res 14 Suppl. 1 (2002) S57-S64
15. Shabsigh R., Seftel A.D., Rosen R.C., Porst H., Ahuja S., Deeley M.C., et al. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction. Urology 68 (2006) 689-696
16. Hemnes A.R., Zaiman A., and Champion H.C. PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am J Physiol 294 (2008) L24-L33
17. Bivalacqua T.J., Burnett A.L., Hellstrom W.J., and Champion H.C. Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity: influence of in vivo gene therapy of anti-arginase. Am J Physiol Heart Circ Physiol 292 (2007) H1340-H1351
18. Tankersley C.G., Champion H.C., Takimoto E., Gabrielson K.L., Bedja D., Misra V., et al. Exposure to inhaled particulate matter impairs cardiac function in senescent mice. Am J Physiol Regul Integr Comp Physiol 295 (2008) R252-R263
19. Hsu L.L., Champion H.C., Campbell-Lee S.A., Bivalacqua T.J., Manci E.A., Diwan B.A., et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 109 (2007) 3088-3098
20. Eckenhoff R.G., Dodia C., Tan Z., and Fisher A.B. Oxygen-dependent reperfusion injury in the isolated rat lung. J Appl Physiol 72 (1992) 1454-1460
21. Korom S., Hillinger S., Cardell M., Zhai W., Tan Q., Dutly A., et al. Sildenafil extends survival and graft function in a large animal lung transplantation model. Eur J Cardiothorac Surg 29 (2006) 288-293
22. Pizanis N., Milekhin V., Tsagakis K., Aleksic I., Kamler M., and Jakob H. PDE-5 inhibitor donor intravenous preconditioning is superior to supplementation in standard preservation solution in experimental lung transplantation. Eur J Cardiothorac Surg 32 (2007) 42-47
23. Dutly A.E., Inci I., Hillinger S., Zalunardo M., Gaspert A., Rousson V., et al. Normal gas exchange after 30-h ischemia and treatment with phosphodiesterase inhibitor PDI747. Eur J Cardiothorac Surg 24 (2003) 594-600
24. Kukreja R.C., Salloum F., Das A., Ockaili R., Yin C., Bremer Y.A., et al. Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications. Vasc Pharmacol 42 (2005) 219-232
25. Kukreja R.C., and Xi L. eNOS phosphorylation: a pivotal molecular switch in vasodilation and cardioprotection?. J Mol Cell Cardiol 42 (2007) 280-282
26. Mount P.F., Kemp B.E., and Power D.A. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol 42 (2007) 271-279
27. Kukreja R.C. Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase. Br J Pharmacol 150 (2007) 538-540
28. Cardella J.A., Keshavjee S.H., Bai X.H., Yeoh J.S., Granton J.T., Meade M.O., et al. Increased expression of nitric oxide synthase in human lung transplants after nitric oxide inhalation. Transplantation 77 (2004) 886-890
29. Liu M., Tremblay L., Cassivi S.D., Bai X.H., Mourgeon E., Pierre A.F., et al. Alterations of nitric oxide synthase expression and activity during rat lung transplantation. Am J Physiol 278 (2000) L1071-L1081
30. Pinsky D.J., Naka Y., Chowdhury N.C., Liao H., Oz M.C., Michler R.E., et al. The nitric oxide/cyclic GMP pathway in organ transplantation: critical role in successful lung preservation. Proc Natl Acad Sci U S A 91 (1994) 12086-12090